Research Analysts Offer Predictions for BLFS Q3 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) - Analysts at HC Wainwright dropped their Q3 2025 earnings per share estimates for shares of BioLife Solutions in a research note issued to investors on Tuesday, May 27th. HC Wainwright analyst Y. Chen now anticipates that the medical equipment provider will earn ($0.04) per share for the quarter, down from their prior estimate of ($0.02). HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. The consensus estimate for BioLife Solutions' current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for BioLife Solutions' Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at $0.02 EPS and Q4 2026 earnings at $0.04 EPS.

Separately, Wall Street Zen cut shares of BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, BioLife Solutions presently has an average rating of "Moderate Buy" and an average target price of $31.17.

BioLife Solutions Stock Down 5.5%

Shares of NASDAQ BLFS traded down $1.20 on Thursday, reaching $20.69. 235,534 shares of the company's stock traded hands, compared to its average volume of 389,089. BioLife Solutions has a 12 month low of $18.70 and a 12 month high of $29.55. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The company has a market cap of $982.54 million, a price-to-earnings ratio of -19.52 and a beta of 2.01. The business's 50 day simple moving average is $22.86 and its two-hundred day simple moving average is $25.09.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.07. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The firm had revenue of $23.94 million during the quarter, compared to the consensus estimate of $22.22 million.

Institutional Investors Weigh In On BioLife Solutions

A number of hedge funds have recently made changes to their positions in the stock. Proficio Capital Partners LLC purchased a new stake in BioLife Solutions during the fourth quarter valued at approximately $638,000. Alliancebernstein L.P. grew its stake in BioLife Solutions by 11.9% during the 4th quarter. Alliancebernstein L.P. now owns 37,351 shares of the medical equipment provider's stock valued at $970,000 after purchasing an additional 3,967 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of BioLife Solutions by 18.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 198,695 shares of the medical equipment provider's stock valued at $5,158,000 after purchasing an additional 31,167 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of BioLife Solutions by 422.2% during the fourth quarter. Victory Capital Management Inc. now owns 218,962 shares of the medical equipment provider's stock worth $5,684,000 after purchasing an additional 177,028 shares during the period. Finally, D.A. Davidson & CO. boosted its position in BioLife Solutions by 1.3% in the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider's stock valued at $1,069,000 after buying an additional 519 shares during the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at BioLife Solutions

In related news, CMO Todd Berard sold 1,577 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $39,425.00. Following the sale, the chief marketing officer now owns 104,961 shares in the company, valued at approximately $2,624,025. This represents a 1.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Aby J. Mathew sold 1,597 shares of BioLife Solutions stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $39,925.00. Following the sale, the executive vice president now owns 260,601 shares of the company's stock, valued at approximately $6,515,025. This trade represents a 0.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,756 shares of company stock valued at $1,660,535. 2.20% of the stock is currently owned by insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.